Therapeutic drug monitoring of daptomycin: A retrospective monocentric analysis

Therapeutic Drug Monitoring

Volumn 37, Issue 5, 2015, Pages 634-640

  Reiber, Claudine ^a   Senn, Oliver ^b   Müller, Daniel ^c   Kullak Ublick, Gerd A ^a   Corti, Natascia ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Gram positive infection; Lipopeptide antibiotic; Therapeutic drug monitoring

Indexed keywords

ALBUMIN; CREATININE; DAPTOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; FEMALE; HEMODIALYSIS; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ANGINOSUS; VANCOMYCIN RESISTANT ENTEROCOCCUS; ADOLESCENT; BLOOD; MIDDLE AGED; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CREATININE; DAPTOMYCIN; DRUG MONITORING; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES;

EID: 84941903322     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000196     Document Type: Article

References (24)

1. Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int J Antimicrob Agents. 2008;32:294-301.
2. La Plante KL, Rybak MJ. Daptomycin-a novel antibiotic against Grampositive pathogens. Expert Opin Pharmacother. 2004;5:2321-2331.
3. Cubicin Product information: FDA; 2013. Available at: http://www.acessdata.fda.gov/drugsatfda-docs/label/2013/021572s043s044lbl. pdf. Accessed March 4, 2015.
4. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-68.
5. Hanberger H, Nilsson LE, Maller R, et al. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991;35:1710-1716.
6. Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013;42:202-210.
7. Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57:1568-1576.
8. Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, et al. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother. 2011;66:912-919.
9. Sakoulas G. Clinical outcomes with daptomycin: a post-marketing, realworld evaluation. Clin Microbiology Infection. 2009;15(suppl 6):11-16.
10. Chaves RL, Chakraborty A, Benziger D, et al. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteremia and severe renal impairment. J Antimicrob Chemother. 2014;69:200-210.
11. Corti N, Rudiger A, Chiesa A, et al. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. Chemotherapy. 2013;59:143-151.
12. Haselden M, Leach M, Bohm N. Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis. Ann Pharmacother. 2013;47:1342-1347.
13. Falcone M, Russo A, Cassetta MI, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother. 2013;19:732-739.
14. Di Paolo A, Tascini C, Polillo M, et al. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents. 2013;42:250-255.
15. Bhavnani SM, Rubino CM, Ambrose PG, et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50:1568-1574.
16. Bubalo JS, Munar MY, Cherala G, et al. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53:428-434.
17. Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. Infection. 2012;40:367-371.
18. Dvorchik B, Arbeit RD, Chung J, et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799-2807.
19. Yabuno K, Seki M, Miyawaki K, et al. High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure. Clin Pharmacol. 2013;5:161-166.
20. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
21. Falcone M, Russo A, Cassetta MI, et al. Daptomycin serum levels in critical patients undergoing continuous renal replacement. J Chemother. 2012;24:253-256.
22. Khadzhynov D, Slowinski T, Lieker I, et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther. 2011;49:656-665.
23. Vilay AM, Grio M, Depestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med. 2011;39:19-25.
24. Wenisch JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous hemodiafiltration. J Antimicrob Chemother. 2012;67:977-983.